Premium
Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in postmortem blood specimens using infectious disease assays licensed for cadaveric donor screening
Author(s) -
Greenwald Melissa A.,
Kerby Stephen,
Francis Kori,
Noller Anna C.,
Gormley William T.,
Biswas Robin,
Forshee Richard A.
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12825
Subject(s) - medicine , virology , hepatitis b virus , hepatitis c virus , virus , nucleic acid test , antibody , hepatitis b , disease , immunology , infectious disease (medical specialty) , pathology , covid-19
Abstract Background Evaluation of assay performance on postmortem blood specimens (obtained after cessation of the heartbeat) presents unique scientific and regulatory challenges. In the United States, assay performance is evaluated in part by spiking postmortem specimens. Methods Fifty‐four specimens obtained from decedents known to be infected with human immunodeficiency virus ( HIV ), hepatitis C virus ( HCV ), or hepatitis B virus ( HBV ), including some coinfections, were tested for each virus using Food and Drug Administration ( FDA )‐licensed donor screening tests for nucleic acid, antibody, and antigen. Results For each disease, >95% of subjects who were reported to have an infection at the time of death had a positive test result on at least one of the donor screening assays for that infection. Conclusion Licensed donor screening tests were positive on postmortem specimens obtained within 24 hours of death from individuals dying with HIV , HCV , and/or HBV , and were able to detect presence of the virus. The use of multiple tests (including antibody and direct viral detection methods) is necessary to adequately evaluate donors.